内容摘要：It was the late 1990s when the family behind Agritopia saw “the writing on the wall,” said Joe Johnston.

It was the late 1990s when the family behind Agritopia saw “the writing on the wall,” said Joe Johnston.

More than three-quarters of patients taking both drugs reported at least one side effect, mostly mild to moderate gastrointestinal issues such as nausea, constipation, diarrhea and vomiting. About 6% of participants taking Zepbound left the trial because of adverse events, compared with 8% of those taking semaglutide.The GLP-1 drugs have become increasingly popular, with at least 1 in 8 U.S. adults reporting their use, according to a 2024 survey by KFF, a independent health policy research organization. Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion (58.2 billlion Danish kroner).

Access and affordability have limited wider use of the drugs. Tirzepatide and semaglutide were removed recently from a list of drug shortages by the U.S. Food and Drug Administration. Both manufacturers recently released programs that cut costs to about $500 per month or less, depending on the dose.Other factors can affect access. This week, CVS Health saidon its standard formulary, or

, as of July 1. Zepbound will be excluded.It’s important to have a range of drugs to treat a disease as widespread as obesity in the U.S., said Dr. Angela Fitch, chief medical officer of knownwell, an obesity care company. Wegovy has been found to cut the risk of serious heart problems by 20%, she noted. A drug may work well for one patient, but not for others.

“We’re going to need to use them all just because we have so many patients who need treatment,” she added.

AP Health Writer Tom Murphy in Indianapolis contributed to this report.“Any of these outbreaks we’re seeing can easily be prevented by increasing the rate of vaccination in the community,” he said. “If we can maintain 95% of people vaccinated, we’re not going to see this happening in the future. And we’ve slipped well below that level in many parts of the country.”

Vaccination rates have declined nationwide since the COVID-19 pandemic, and most states are below the— the level needed to protect communities against measles outbreaks.

Not usually. People who are vaccinated are considered protected against measles for their lifetime.Health care providers can test for antibodies and give boosters if needed.